Centene (NYSE:CNC) Updates FY 2025 Earnings Guidance

Centene (NYSE:CNC) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 7.250- for the period, compared to the consensus EPS estimate of 7.250. The company issued revenue guidance of -.

Centene Stock Performance

Shares of NYSE CNC opened at $60.82 on Thursday. Centene has a 1 year low of $55.03 and a 1 year high of $81.42. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.10. The firm has a market cap of $30.71 billion, a P/E ratio of 10.56, a PEG ratio of 0.85 and a beta of 0.45. The stock has a fifty day moving average price of $61.28 and a two-hundred day moving average price of $67.06.

Centene (NYSE:CNC) last issued its quarterly earnings results on Tuesday, February 4th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.31. Centene had a return on equity of 13.32% and a net margin of 1.90%. The firm had revenue of $40.81 billion for the quarter, compared to analysts’ expectations of $38.78 billion. During the same quarter last year, the business posted $0.45 EPS. Centene’s revenue was up 3.4% on a year-over-year basis. Research analysts forecast that Centene will post 6.82 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $75.00 target price (down previously from $80.00) on shares of Centene in a research note on Tuesday, December 17th. StockNews.com raised shares of Centene from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 27th. Argus downgraded Centene from a “buy” rating to a “hold” rating in a research note on Thursday. UBS Group raised Centene from a “neutral” rating to a “buy” rating and raised their price target for the stock from $79.00 to $80.00 in a research note on Friday, December 13th. Finally, Robert W. Baird increased their price objective on Centene from $66.00 to $71.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Centene presently has an average rating of “Moderate Buy” and a consensus target price of $81.31.

Insider Activity

In related news, CFO Andrew Lynn Asher purchased 17,200 shares of the stock in a transaction on Wednesday, November 13th. The shares were purchased at an average cost of $58.14 per share, for a total transaction of $1,000,008.00. Following the completion of the transaction, the chief financial officer now directly owns 486,847 shares of the company’s stock, valued at approximately $28,305,284.58. The trade was a 3.66 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas Greco bought 17,000 shares of Centene stock in a transaction dated Wednesday, December 18th. The stock was purchased at an average price of $59.75 per share, for a total transaction of $1,015,750.00. Following the purchase, the director now directly owns 19,309 shares in the company, valued at $1,153,712.75. This represents a 736.25 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 45,010 shares of company stock worth $2,660,276. Company insiders own 0.29% of the company’s stock.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.